Nile Therapeutics, Inc. (Nasdaq: NLTX) today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE